Good morning, everyone, and how are you today? We are doing just fine, thank you, helped along by a warm and shiny sun enveloping the otherwise chilly Pharmalot campus. This gives us hope that spring is near. Meanwhile, though, we are keeping busy with the usual sundry tasks and firing up the trusty coffee kettle for cups of stimulation. After all, there is much to be done and, no doubt, you can relate. So here is the lovingly assembled menu of tidbits to help you along. Have a smashing day and do keep in touch….

The head of the Sandoz generic unit at Novartis (NVS) is quitting after the drug maker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spinoff or sale, Reuters tells us. Richard Francis ran the unit since 2014. Sandoz last year sold a U.S. pills and dermatology portfolio to Aurobindo and began a “de-integration” of the division from the rest of Novartis, a process that is expected to stretch into 2020 and clear the way for talks about the future of the unit. Francesco Balestrieri, who heads Sandoz in Europe, will run the business.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy